OptimizeRx Details CCO Separation Agreement, $589K Payout
OPRX is trading near its 52-week low of $4.57 (12% above the low).
Summary
OptimizeRx disclosed the financial terms of its Chief Commercial Officer's separation, including a $589,000 payout and an advisory agreement with non-compete clauses.
Key Events · Executive and Board Changes · OPRX
-
CCO Departure Terms Finalized
Theresa Greco's separation as Chief Commercial Officer is effective June 15, 2026, with the financial terms now detailed, following previous disclosure in the Q1 2026 10-Q.
-
Significant Severance Package
Ms. Greco will receive $380,000 in base salary continuation for 12 months and a $209,000 lump sum annual cash bonus, totaling $589,000, plus reimbursement for COBRA premiums for 12 months.
-
Advisory Role and Non-Compete
Ms. Greco will provide advisory services to the company for 12 months, during which her previously granted equity will continue to vest. She is also subject to a 12-month non-compete and non-solicit agreement.
Analysis · OPRX · Trade & Services
This 8-K provides the financial terms of Chief Commercial Officer Theresa Greco's separation, which was previously disclosed. The company will pay Ms. Greco a total of $589,000 in salary continuation and bonus, plus COBRA benefits, over the next year. She will also provide advisory services and be subject to a non-compete clause, which helps mitigate the impact of her departure. The cost represents a notable expense for the company.
At the time of this filing, OPRX was trading at $5.11 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $95.9M. The 52-week trading range was $4.57 to $22.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.